Preadmission Statin Use Does Not Improve Functional Outcomes or Prevent Delayed Ischemic Events in Patients with Spontaneous Subarachnoid Hemorrhage
Authors:
- 7 May 2014
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 34 (8) , 811-817
Abstract
Study Objective: To determine whether preadmission statin use in patients with spontaneous subarachnoid hemorrhage (SAH) is associated with improved functional outcomes and a lower incidence of delayed cerebral ischemic events compared with statin‐naive patients with SAH.Design: Prospective cohort study.Setting: Neurosciences intensive care unit of a tertiary care hospital.Patients: A total of 295 consecutive patients with SAH admitted between March 2006 and May 2013 who had complete medication histories; of these patients, 41 reported taking a statin prior to admission, and 254 were statin naive.Intervention: All patients received clinical management for SAH according to hospital protocol for standard care that included acute statin therapy with enteral pravastatin 40 mg/day on hospital day 1 for up to 21 days.Measurements and Main Results: Functional outcomes were assessed by using the modified Rankin Scale (mRS) at 14 days, 28 days, and 3 months. Delayed cerebral ischemia was assessed by using clinical evaluation and computed tomography. Patients taking statins prior to admission were more likely to have a history of diabetes mellitus, hypertension, coronary artery disease, and stroke. No significant difference in favorable neurologic outcome (mRS score 0–3) at 3 months was observed between the preadmission statin group compared with the statin‐naive group (56.3% vs 72.4%, p=0.095). In multivariate logistic regression analysis, only age, severity of rupture, and coronary artery disease were less likely to predict a favorable neurologic outcome. No significant difference in the development of delayed cerebral ischemic events was observed between groups (p=0.48).Conclusion: Statin use prior to admission did not improve functional outcomes or prevent delayed cerebral ischemic events in patients with SAH. Age, severity of rupture, and coronary artery disease were less likely to predict a favorable neurologic outcome at 3 months after discharge.Keywords
This publication has 28 references indexed in Scilit:
- Simvastatin Re-Couples Dysfunctional Endothelial Nitric Oxide Synthase in Experimental Subarachnoid HemorrhagePLOS ONE, 2011
- Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a systematic reviewCritical Care, 2010
- Effect of Statin Treatment on Vasospasm, Delayed Cerebral Ischemia, and Functional Outcome in Patients With Aneurysmal Subarachnoid HemorrhageStroke, 2010
- Withdrawal of Statins and Risk of Subarachnoid HemorrhageStroke, 2009
- Prehemorrhage statin use and the risk of vasospasm after aneurysmal subarachnoid hemorrhageSurgical Neurology, 2009
- A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Simvastatin in Aneurysmal Subarachnoid HemorrhageStroke, 2008
- Do Statins Improve Outcomes and Reduce the Incidence of Vasospasm After Aneurysmal Subarachnoid HemorrhageStroke, 2008
- Effects of Acute Pravastatin Treatment on Intensity of Rescue Therapy, Length of Inpatient Stay, and 6-Month Outcome in Patients After Aneurysmal Subarachnoid HemorrhageStroke, 2007
- Outcomes Validity and Reliability of the Modified Rankin Scale: Implications for Stroke Clinical TrialsStroke, 2007
- Improving the Assessment of Outcomes in StrokeStroke, 2002